Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

In addition, Aleta has developed proprietary and novel co-stimulatory multi-antigen CTEs (CO-CTEs) that contain additional binding domains for CD2, CD28 and/or other T-cell co-receptors for co ...

"We looked at two different types of CAR T cells. The first, CD28.ζ-CART cells, are like sprinters. They kill cancer cells quickly and efficiently, but their activity is short-lived. The second ...

Jain said that co-stimulation is also a key factor in activating T cells, and products that use CD28 for co-stimulation are ...

or CD3/CD28 magnetic beads, along with the addition of relevant growth factors to activate T cells. During this process, the CD28-mediated co-stimulatory signal plays a central role. Multiple studies ...

XmAb808 (B7-H3 x CD28), a bispecific antibody to provide conditional co-stimulation of T cells when also bound to tumor cells. Dose escalation in an ongoing Phase 1 study combining XmAb808 with ...

Just as the human body has mechanisms to activate T cells, it also has inhibition mechanisms that help regulate the immune system and prevent excessive activity such as autoimmune reactions. This ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human ... Platform to develop a pipeline of novel CD3 and CD28 ...